Cargando…

Administration of Menadione, Vitamin K3, Ameliorates Off-Target Effects on Corneal Epithelial Wound Healing Due to Receptor Tyrosine Kinase Inhibition

PURPOSE: The antiangiogenic receptor tyrosine kinase inhibitor (RTKi), 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[[4-(1-pyrrolidinyl) butyl] amino] carbonyl]amino]-4-isothiazolecarboxamide hydrochloride, targets VEGFR2 (half maximal inhibitory concentration [IC(50)] = 11 nM); however, off-target i...

Descripción completa

Detalles Bibliográficos
Autores principales: Rush, Jamie S., Bingaman, David P., Chaney, Paul G., Wax, Martin B., Ceresa, Brian P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733502/
https://www.ncbi.nlm.nih.gov/pubmed/27802516
http://dx.doi.org/10.1167/iovs.16-19952
_version_ 1783449996107972608
author Rush, Jamie S.
Bingaman, David P.
Chaney, Paul G.
Wax, Martin B.
Ceresa, Brian P.
author_facet Rush, Jamie S.
Bingaman, David P.
Chaney, Paul G.
Wax, Martin B.
Ceresa, Brian P.
author_sort Rush, Jamie S.
collection PubMed
description PURPOSE: The antiangiogenic receptor tyrosine kinase inhibitor (RTKi), 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[[4-(1-pyrrolidinyl) butyl] amino] carbonyl]amino]-4-isothiazolecarboxamide hydrochloride, targets VEGFR2 (half maximal inhibitory concentration [IC(50)] = 11 nM); however, off-target inhibition of epidermal growth factor receptor (EGFR) occurs at higher concentrations. (IC(50) = 5.8 μM). This study was designed to determine the effect of topical RTKi treatment on EGF-mediated corneal epithelial wound healing and to develop new strategies to minimize off-target EGFR inhibition. METHODS: In vitro corneal epithelial wound healing was measured in response to EGF using a transformed human cell line (hTCEpi cells). In vivo corneal wound healing was assessed using a murine model. In these complementary assays, wound healing was measured in the presence of varying RTKi concentrations. Immunoblot analysis was used to examine EGFR and VEGFR2 phosphorylation and the kinetics of EGFR degradation. An Alamar Blue assay measured VEGFR2-mediated cell biology. RESULTS: Receptor tyrosine kinase inhibitor exposure caused dose-dependent inhibition of EGFR-mediated corneal epithelial wound healing in vitro and in vivo. Nanomolar concentrations of menadione, a vitamin K3 analog, when coadministered with the RTKi, slowed EGFR degradation and ameliorated the inhibitory effects on epithelial wound healing both in vitro and in vivo. Menadione did not alter the RTKi's IC(50) against VEGFR2 phosphorylation or its inhibition of VEGF-induced retinal endothelial cell proliferation. CONCLUSIONS: An antiangiogenic RTKi exhibited off-target effects on the corneal epithelium that can be minimized by menadione without deleteriously affecting its on-target VEGFR2 blockade. These data indicate that menadione has potential as a topical supplement for individuals suffering from perturbations in corneal epithelial homeostasis, especially as an untoward side effect of kinase inhibitors.
format Online
Article
Text
id pubmed-6733502
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher The Association for Research in Vision and Ophthalmology
record_format MEDLINE/PubMed
spelling pubmed-67335022019-09-19 Administration of Menadione, Vitamin K3, Ameliorates Off-Target Effects on Corneal Epithelial Wound Healing Due to Receptor Tyrosine Kinase Inhibition Rush, Jamie S. Bingaman, David P. Chaney, Paul G. Wax, Martin B. Ceresa, Brian P. Invest Ophthalmol Vis Sci Cornea PURPOSE: The antiangiogenic receptor tyrosine kinase inhibitor (RTKi), 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[[4-(1-pyrrolidinyl) butyl] amino] carbonyl]amino]-4-isothiazolecarboxamide hydrochloride, targets VEGFR2 (half maximal inhibitory concentration [IC(50)] = 11 nM); however, off-target inhibition of epidermal growth factor receptor (EGFR) occurs at higher concentrations. (IC(50) = 5.8 μM). This study was designed to determine the effect of topical RTKi treatment on EGF-mediated corneal epithelial wound healing and to develop new strategies to minimize off-target EGFR inhibition. METHODS: In vitro corneal epithelial wound healing was measured in response to EGF using a transformed human cell line (hTCEpi cells). In vivo corneal wound healing was assessed using a murine model. In these complementary assays, wound healing was measured in the presence of varying RTKi concentrations. Immunoblot analysis was used to examine EGFR and VEGFR2 phosphorylation and the kinetics of EGFR degradation. An Alamar Blue assay measured VEGFR2-mediated cell biology. RESULTS: Receptor tyrosine kinase inhibitor exposure caused dose-dependent inhibition of EGFR-mediated corneal epithelial wound healing in vitro and in vivo. Nanomolar concentrations of menadione, a vitamin K3 analog, when coadministered with the RTKi, slowed EGFR degradation and ameliorated the inhibitory effects on epithelial wound healing both in vitro and in vivo. Menadione did not alter the RTKi's IC(50) against VEGFR2 phosphorylation or its inhibition of VEGF-induced retinal endothelial cell proliferation. CONCLUSIONS: An antiangiogenic RTKi exhibited off-target effects on the corneal epithelium that can be minimized by menadione without deleteriously affecting its on-target VEGFR2 blockade. These data indicate that menadione has potential as a topical supplement for individuals suffering from perturbations in corneal epithelial homeostasis, especially as an untoward side effect of kinase inhibitors. The Association for Research in Vision and Ophthalmology 2016-11 /pmc/articles/PMC6733502/ /pubmed/27802516 http://dx.doi.org/10.1167/iovs.16-19952 Text en http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
spellingShingle Cornea
Rush, Jamie S.
Bingaman, David P.
Chaney, Paul G.
Wax, Martin B.
Ceresa, Brian P.
Administration of Menadione, Vitamin K3, Ameliorates Off-Target Effects on Corneal Epithelial Wound Healing Due to Receptor Tyrosine Kinase Inhibition
title Administration of Menadione, Vitamin K3, Ameliorates Off-Target Effects on Corneal Epithelial Wound Healing Due to Receptor Tyrosine Kinase Inhibition
title_full Administration of Menadione, Vitamin K3, Ameliorates Off-Target Effects on Corneal Epithelial Wound Healing Due to Receptor Tyrosine Kinase Inhibition
title_fullStr Administration of Menadione, Vitamin K3, Ameliorates Off-Target Effects on Corneal Epithelial Wound Healing Due to Receptor Tyrosine Kinase Inhibition
title_full_unstemmed Administration of Menadione, Vitamin K3, Ameliorates Off-Target Effects on Corneal Epithelial Wound Healing Due to Receptor Tyrosine Kinase Inhibition
title_short Administration of Menadione, Vitamin K3, Ameliorates Off-Target Effects on Corneal Epithelial Wound Healing Due to Receptor Tyrosine Kinase Inhibition
title_sort administration of menadione, vitamin k3, ameliorates off-target effects on corneal epithelial wound healing due to receptor tyrosine kinase inhibition
topic Cornea
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733502/
https://www.ncbi.nlm.nih.gov/pubmed/27802516
http://dx.doi.org/10.1167/iovs.16-19952
work_keys_str_mv AT rushjamies administrationofmenadionevitamink3amelioratesofftargeteffectsoncornealepithelialwoundhealingduetoreceptortyrosinekinaseinhibition
AT bingamandavidp administrationofmenadionevitamink3amelioratesofftargeteffectsoncornealepithelialwoundhealingduetoreceptortyrosinekinaseinhibition
AT chaneypaulg administrationofmenadionevitamink3amelioratesofftargeteffectsoncornealepithelialwoundhealingduetoreceptortyrosinekinaseinhibition
AT waxmartinb administrationofmenadionevitamink3amelioratesofftargeteffectsoncornealepithelialwoundhealingduetoreceptortyrosinekinaseinhibition
AT ceresabrianp administrationofmenadionevitamink3amelioratesofftargeteffectsoncornealepithelialwoundhealingduetoreceptortyrosinekinaseinhibition